STOCK TITAN

Perceptive group reports 4.6% Bright Minds (DRUG) ownership in 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Bright Minds Biosciences Inc. received an amended Schedule 13G showing that Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. jointly report beneficial ownership of 449,290 common shares, or 4.6% of the class. This percentage is based on 9,732,161 common shares outstanding as reported in a recent prospectus supplement. The filing states the securities are not held for the purpose of changing or influencing control of the company.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:02/17/2026
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:02/17/2026

FAQ

What ownership stake in DRUG does Perceptive report on this Schedule 13G/A?

Perceptive reports beneficial ownership of 449,290 common shares of Bright Minds Biosciences Inc., representing 4.6% of the outstanding class. This stake is held through Perceptive Life Sciences Master Fund, with Perceptive Advisors as investment manager and Joseph Edelman as managing member.

Which entities are the reporting persons on the Bright Minds (DRUG) Schedule 13G/A?

The filing lists three reporting persons: Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd.. The Master Fund directly holds the shares, Perceptive Advisors serves as its investment manager, and Edelman is the managing member of Perceptive Advisors.

How was the 4.6% ownership in Bright Minds (DRUG) calculated?

The 4.6% ownership figure is based on 9,732,161 common shares of Bright Minds Biosciences outstanding. That share count comes from a prospectus supplement filed on January 9, 2026, which reflects completion of an offering and full exercise of the underwriters’ over-allotment option.

Does the Perceptive filing indicate intent to influence control of Bright Minds (DRUG)?

The certification explicitly states the securities were not acquired and are not held for the purpose of changing or influencing control of Bright Minds Biosciences. It also notes they are not held in connection with any transaction having that control-related purpose, other than certain nomination activities.

What voting and dispositive power does Perceptive report over DRUG shares?

The reporting persons show no sole voting or dispositive power over Bright Minds shares. They report shared voting power for 449,290 shares and shared dispositive power for the same 449,290 shares, reflecting coordinated authority among the listed reporting persons for these common shares.

Why does the Bright Minds (DRUG) Schedule 13G/A mention ownership of 5 percent or less?

Item 5 states ownership of 5 percent or less of a class. This confirms the reported beneficial ownership in Bright Minds common shares is below the 5% threshold, consistent with the 4.6% figure calculated from the disclosed outstanding share count in the referenced prospectus supplement.
Bright Minds Biosciences Inc

NASDAQ:DRUG

DRUG Rankings

DRUG Latest News

DRUG Latest SEC Filings

DRUG Stock Data

758.14M
9.73M
Biotechnology
Healthcare
Link
United States
New York